Christopher R. Fenimore, SVP Finance & CFO at REGENERON PHARMACEUTICALS, INC. (REGN), sold 10,760 shares at $1204.79 ($13.0M) on 2024-08-28, disclosed to the SEC on 2024-08-29.
Open-market sale of $13.0M REGN by SVP Finance & CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1204.71 | 2,237 | $2.7M | 20.8% |
| 2 | $1204.71 | 2,237 | $2.7M | 20.8% |
| 3 | $1204.79 | 228 | $275K | 2.1% |
| 4 | $1204.79 | 228 | $275K | 2.1% |
| 5 | $1205.44 | 766 | $923K | 7.1% |
| 6 | $1205.44 | 766 |
| $923K |
| 7.1% |
| 7 | $1205.49 | 928 | $1.1M | 8.6% |
| 8 | $1205.49 | 928 | $1.1M | 8.6% |
| 9 | $1205.67 | 236 | $285K | 2.2% |
| 10 | $1205.67 | 235 | $283K | 2.2% |
| 11 | $1205.67 | 235 | $283K | 2.2% |
| 12 | $1205.67 | 236 | $285K | 2.2% |
| 13 | $1206.15 | 450 | $543K | 4.2% |
| 14 | $1206.15 | 450 | $543K | 4.2% |
| 15 | $1206.30 | 200 | $241K | 1.9% |
| 16 | $1206.67 | 200 | $241K | 1.9% |
| 17 | $1206.70 | 200 | $241K | 1.9% |
| Total | $1205.26 avg | 10,760 | $13.0M | 100% |
| Filing → |
| REGN | SELL | 2023-12-26 | $3.3M | — | Filing → |
| REGN | SELL | 2023-03-27 | $3.5M | — | Filing → |
| REGN | SELL | 2022-10-07 | $1.4M | — | Filing → |